A screen for IgG anti-nuclear antibodies (ANA) by indirect immunofluorescence on HEp-2 cells confirmed a highly significant overrepresentation of ANA in the cancer group where 40% had detectable (i.e., a titer ≥160) ANA compared with less than 12% in the benign group.
← all excerpts
Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
1
—
—